Modafinil: preclinical, clinical, and post-marketing surveillance--a review of abuse liability issues
Myrick H, Malcolm R, Taylor B, LaRowe S.
Department of Psychiatry and Behavioral Sciences,
Medical University of South Carolina,
Charleston, South Carolina 29425, USA.
Ann Clin Psychiatry. 2004 Apr-Jun;16(2):101-9.
ABSTRACTModafinil is an agent that is frequently used in the treatment of narcolepsy. More recently it has been used in the treatment of a variety of psychiatric, neurological, and medical illnesses. Due to its ability to improve wakefulness, modafinil has been viewed as a stimulant. Based on the potential for modafinil to become widely used in a variety of syndromes and settings, evidence from preclinical in vitro and in vivo studies, human laboratory studies, and post-marketing experiences examining the potential abuse liability of modafinil were reviewed. Initial evidence suggests that modafinil has limited potential for large-scale abuse.
Modafinil and serotonin
Modafinil and the marmoset
Excessive daytime sleepiness
Modafinil as an antidepressant
Modafinil versus amphetamine
Modafinil versus methylphenidate
Modafinil, amphetamine and sleep
Fatigue, sleepiness in major depression